Life Sciences & Healthcare
D&I and 13 of its lawyers recognized by Best Lawyers® in the 8th edition of The Best Lawyers in Finland for the following listed categories: Environmental Law, Biotechnology Law, Mergers and Acquisitions Law, Private Equity Law, Corporate Law, Information Technology Law, Media Law, Technology Law, Telecommunications Law, Tax Law, Banking and Finance Law, Arbitration and Mediation, Competition Law, Labor and Employment Law and Litigation.
D&I Alert: The Finnish Government Publishes Proposal on Patient's Freedom of Choice
D&I's Partner Johan Åkermarck, Head of Life Sciences & Healthcare, has been recognized as a leading expert in the Who’s Who Legal 2017 editions of: Life Sciences - Transactional and Life Sciences - Regulatory . Who's Who Legal identifies the foremost legal practitioners in business law based upon comprehensive, independent research.
D&I Alert: The Finnish Government Publishes Draft Proposal on Patient's Freedom of Choice
D&I Life Sciences Alert by D&I's Partner Johan Åkermarck and the Life Sciences & Healthcare practice on the latest Finnish updates 2015 of this practice area.
D&I advises Adelis Equity Partners Fund I in its acquisition of a majority stake in Med Group Oy, one of the fastest growing healthcare services companies in Finland, from Terveysrahasto Oy and the company’s two founders. The founders together with the broader management team continue to own a significant part of the company. The company caters to the public sector as well as individual customers across Finland.
D&I advised Karolinska Development AB, the Swedish listed Life Sciences company when it closed its financing round in the Finnish drug development company Forendo Pharma Oy, which announced the successful closing of the EUR 12 million financing round. Novartis Venture Fund and MS Ventures participates in the financing round, alongside the current major shareholders Karolinska Development AB, Novo Seeds and Finnvera.
We advised Karolinska Development, a Swedish listed medical company, in its investment into Forendo Pharma, a new drug development company based in Finland.
D&I advised Mendor, a leading company in new diabetes technologies and services, in relation to its EUR 8.1 million venture capital financing.
D&I continuously advises some of the world's leading pharmaceutical companies in all fields of Finnish pharmaceutical and business law.
We advised an orphan drug company with the legal aspects relating to entering the Finnish market.
D&I advises several of the world's leading medical device companies in all fields of their Finnish life sciences businesses.
We have represented leading international pharmaceutical companies in the establishment, acquisition and reorganization of operations in Finland, including regulatory, corporate and contractual work.
We acted for a Nordic state-controlled distributor of pharmaceuticals in its cross-border merger with a leading Finnish distributor, creating the largest pharmaceuticals distributor in the Nordic countries.
We advised a pioneering biotechnology venture in Finland in all legal aspects of its operations, including capitalization, public funding, and patents and other intellectual property.
D&I advises Finnish private equity firm MB Funds and other owners in the sale of Finland's largest social care services company Mainio Vire (formerly Medivire Hoiva) to British private equity investor HgCapital.
We advised a pharmaceutical company with subsidy issues before the Pharmaceutical Pricing Board.
D&I advises private hospitals on compliance issues and medical practice issues.
D&I advised the seller of Medivire Työterveyspalvelut, a major healthcare company, in a EUR 127 million sale to Suomen Terveystalo.
D&I advised Ratos, the Swedish listed private equity house, in the EUR 67 million acquisition of the Health Care Division of Perlos, the leading Finnish contract manufacturer and the related EUR 60 million add-on acquisition of Medisize, a Swiss healthcare company.
D&I continuously advises companies in the pharmaceutical field, for instance, relating to dominance issues, distribution arrangements and public procurement matters.
D&I advises AstraZeneca in the Finnish aspects of its approximately USD 1.8 billion cash sale of Astra Tech to DENTSPLY International.